State Street Corp Acquires 113,095 Shares of Catalent, Inc. (NYSE:CTLT)

State Street Corp lifted its stake in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 1.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,451,135 shares of the company's stock after acquiring an additional 113,095 shares during the quarter. State Street Corp owned about 4.11% of Catalent worth $451,315,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CTLT. Athos Capital Ltd acquired a new stake in Catalent during the third quarter valued at approximately $6,009,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Catalent in the 3rd quarter worth $1,131,000. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Catalent by 3.7% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company's stock worth $24,550,000 after acquiring an additional 14,373 shares during the last quarter. Quest Partners LLC lifted its holdings in shares of Catalent by 289.8% during the third quarter. Quest Partners LLC now owns 49,300 shares of the company's stock valued at $2,986,000 after purchasing an additional 36,652 shares during the last quarter. Finally, Quarry LP acquired a new position in shares of Catalent in the 3rd quarter valued at $4,482,000.

Catalent Stock Performance

Shares of CTLT traded down $0.13 during mid-day trading on Tuesday, hitting $62.24. The company's stock had a trading volume of 1,733,462 shares, compared to its average volume of 2,051,029. The stock's 50-day moving average is $60.10 and its two-hundred day moving average is $58.80. The firm has a market capitalization of $11.30 billion, a PE ratio of -27.60, a price-to-earnings-growth ratio of 2.46 and a beta of 1.15. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. Catalent, Inc. has a one year low of $36.74 and a one year high of $62.50.

Catalent (NYSE:CTLT - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm's quarterly revenue was up 4.2% compared to the same quarter last year. During the same period last year, the business earned ($0.10) earnings per share. As a group, sell-side analysts anticipate that Catalent, Inc. will post 0.84 EPS for the current year.

Insider Buying and Selling

In other news, insider David Mcerlane sold 1,994 shares of the firm's stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Michelle R. Ryan sold 2,800 shares of the company's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,114 shares of company stock valued at $305,931 over the last quarter. Corporate insiders own 0.31% of the company's stock.

Analyst Ratings Changes

Several analysts have recently commented on the company. Baird R W cut Catalent from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. StockNews.com downgraded shares of Catalent from a "hold" rating to a "sell" rating in a research report on Tuesday. Robert W. Baird reiterated a "neutral" rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. Finally, William Blair restated a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $63.40.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.